Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8754224 | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
US7495103 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8629162 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Jun, 2025
(1 year, 1 month from now) | |
US8354427 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Jul, 2026
(2 years from now) | |
US9670163 | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
US8410274 | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
US8324242 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Aug, 2027
(3 years from now) | |
US11564916 | VERTEX PHARMS | Pharmaceutical composition and administrations thereof |
Aug, 2029
(5 years from now) | |
US10646481 | VERTEX PHARMS | Pharmaceutical composition and administrations thereof |
Aug, 2029
(5 years from now) |
Kalydeco is owned by Vertex Pharms.
Kalydeco contains Ivacaftor.
Kalydeco has a total of 9 drug patents out of which 0 drug patents have expired.
Kalydeco was authorised for market use on 20 May, 2019.
Kalydeco is available in tablet;oral dosage forms.
Kalydeco can be used as treatment of cf in a patient age 6 years and older who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 11564916, method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide, use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data, method of treating cystic fibrosis.
Drug patent challenges can be filed against Kalydeco from 01 February, 2016.
The generics of Kalydeco are possible to be released after 13 August, 2029.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
New Indication(I-705) | Dec 30, 2017 |
Orphan Drug Exclusivity(ODE-187) | Dec 29, 2021 |
Orphan Drug Exclusivity(ODE-186) | Feb 21, 2021 |
New Indication(I-740) | Feb 21, 2017 |
New Patient Population(NPP) | Jul 31, 2020 |
Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
Drugs and Companies using
IVACAFTOR ingredient
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8754224 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
US7495103 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8629162 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2025
(1 year, 1 month from now) | |
US8354427 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jul, 2026
(2 years from now) | |
US8410274 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
US9670163 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
US8324242 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Aug, 2027
(3 years from now) | |
US10646481 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(5 years from now) | |
US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(5 years from now) | |
US8883206 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
US10272046 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
US11147770 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
US11752106 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) |
Kalydeco is owned by Vertex Pharms Inc.
Kalydeco contains Ivacaftor.
Kalydeco has a total of 13 drug patents out of which 0 drug patents have expired.
Kalydeco was authorised for market use on 03 May, 2023.
Kalydeco is available in granule;oral dosage forms.
Kalydeco can be used as treatment of cf in a patient age 4 months to <6 years who has one cftr mutation responsive to ivacaftor based on clinical and/or in vitro assay data using a solid composition comprising amorphous (less than about 30% crystalline) ivacaftor, treatment of cf in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 11147770, treatment of a moderate to mild clinical phenotype of cf using ivacaftor in a patient age 4 months to <6 years who has one cftr mutation responsive to ivacaftor based on clinical and/or in vitro assay data, treatment of cystic fibrosis using ivacaftor in a patient age 1 month to <4 months who has a r117h mutation in the cftr gene, treatment of cf in a patient age 1 month to <6 years who has at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 11752106, treatment of cf in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 11564916, treatment of cystic fibrosis using ivacaftor in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data, treatment of cf in a patient age 6 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 10272046.
Drug patent challenges can be filed against Kalydeco from 01 February, 2016.
The generics of Kalydeco are possible to be released after 27 February, 2033.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
Orphan Drug Exclusivity(ODE-236) | Apr 29, 2026 |
Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
Orphan Drug Exclusivity(ODE-435) | May 03, 2030 |
New Patient Population(NPP) | Apr 29, 2022 |
New Indication(I-740) | Feb 21, 2017 |
Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
Orphan Drug Exclusivity(ODE-188) | Mar 17, 2022 |
Drugs and Companies using
IVACAFTOR ingredient